Germany’s Federal Ministry of Education and Research (BMBF) has provided a grant of €2.6m for a study exploring the efficacy of psilocybin as a treatment for...
Psychedelics venture studio Nucleus has raised USD$135,000 from investors through its Wefunder campaign.
Former Red Bull Canada and Juul Labs Canada executive, Nicholas Kadysh, has been appointed to the role of Executive Special Advisor by Clearmind Medicine.
Data from Diamond Therapeutics’ trial is the first to identify a safe, active and non-psychedelic dosage of psilocybin, which the company says could open the possibility...
BetterLife Pharma has secured investment from Negev Capital and further European investors that will go towards working capital purposes and the advancement of pre-clinical and clinical...
COMPASS Pathways has presented new, positive data demonstrating the potential of COMP360 psilocybin therapy in depression at the Annual Meeting of the American College of Neuropsychopharmacology...
Filament Health has been issued two new patents for the extraction and standardisation of natural psilocybin and associated psychedelic compounds.
A team of researchers at the University of Pennsylvania School of Medicine have published findings which show how ketamine dramatically reorganises activity in the brain –...
Awakn Life Sciences has announced that it has signed a five-year lease to open Awakn Clinics Trondheim.
Psyrise, a mental health marketing company located in South Florida, has released a first-of-its-kind marketing platform for health practitioners in the field of psychedelic therapies.